Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2021-09-09 Major Shareholding Noti…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically related to convertible bonds and put options) by Kiwoom Private Equity and its special related parties in the company PharmAbcine. This document type is specifically designed to notify the market of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2021-09-09 Korean
투자판단관련주요경영사항(전이성 삼중 음성 유방암 환자에서 펨브롤리주맙과 병용한 올린베시맙의 제2상, 공개, 다기관 임상시험계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (PharmAbcine) regarding the approval of a Phase 2 clinical trial for a drug combination. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market, which is a mandatory disclosure of significant corporate events. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2021-09-03 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details a change in the contract end date. Since this is a specific regulatory disclosure regarding a contract amendment that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2021-08-31 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제1회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (PharmAbcine) detailing the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This involves a change in the company's capital structure and debt obligations. Since it specifically relates to the company's financing activities and capital structure adjustments, it falls under the 'Capital/Financing Update' category.
2021-08-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). It details the share ownership and changes in holdings for a specific director (Lee Dong-sup) of PharmAbcine. This type of filing is a standard regulatory disclosure for insider share transactions, which falls under the 'Director's Dealing' category.
2021-08-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard regulatory disclosure for insider share ownership changes, which falls under the 'Director's Dealing' category in the provided schema.
2021-08-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.